GLO1 and neoplasm: Besides, while initial studies with proliferating lymphocytes in vitro and tumor‐bearing mice suggested that adverse effects are limited,[75] normal‐tissue toxicity or compensatory mechanisms should be considered when proposing GLO1 inhibitors for cancer therapy since GLO1 is broadly relevant to cellular metabolism.